GSK’s Tykerb gets priority review

Share this article:
The designation means a decision on Glaxo’s application must come within six months of the drug’s filing date with the FDA, which was Sept. 18. Glaxo is seeking to market Tykerb as a treatment to be used in combination with Roche’s Xeloda for breast cancer that has spread to other parts of the body. Tykerb, if approved, would compete with Roche and Genentech’s rival drug Herceptin. Analysts predict that Tykerb be a $4 billion-a-year seller, depending on how it performs against Herceptin.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.